Forte Biosciences (FBRX)
(Delayed Data from NSDQ)
$10.30 USD
-0.28 (-2.65%)
Updated Aug 7, 2025 03:59 PM ET
After-Market: $10.27 -0.03 (-0.29%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FBRX 10.30 -0.28(-2.65%)
Will FBRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FBRX
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
FBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for FBRX
Sixteen new option listings on July 23rd
FEDERATED HERMES, INC. Acquires 1,072,233 Shares in Forte Biosciences Inc
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Forte Biosciences Announces Public Offering of Shares